China has deployed AI-assisted cancer screening at a scale few countries can match. Here is what the technology landscape looks like — and why it matters for international patients.
China diagnoses approximately 3.25 million new cancer cases per year — one of the highest totals globally. With a radiologist-to-population ratio that remains below international recommendations in many provinces, the challenge of early detection is fundamentally a capacity problem. AI-assisted screening has emerged as China's large-scale response.
The Scale Problem That Created the AI Opportunity
China diagnoses approximately 3.25 million new cancer cases per year — one of the highest totals globally. With a radiologist-to-population ratio that remains below international recommendations in many provinces, the challenge of early detection is fundamentally a capacity problem. AI-assisted screening has emerged as China's large-scale response.
Between 2018 and 2024, Chinese hospitals and technology companies deployed AI diagnostic tools across hundreds of institutions. The resulting clinical experience has been published in peer-reviewed journals and tracked by the NMPA through its medical AI device approval process.
Lung Cancer: The Most Mature Application
Lung cancer is China's leading cause of cancer death, with approximately 750,000 fatalities per year. Low-dose CT (LDCT) screening has strong evidence for mortality reduction, but interpreting large volumes of chest CT scans requires radiologist expertise that is unevenly distributed across China's vast geography.
Infervision — one of China's pioneering medical AI companies — has developed the InferRead CT Lung system for pulmonary nodule detection and triage. The system has been deployed in over 400 hospitals across China and internationally, and has been evaluated in multiple peer-reviewed validation studies. Published results consistently show that AI assistance improves the sensitivity of junior radiologists while reducing per-scan reading time — two clinically meaningful outcomes in high-volume settings.
China's National Cancer Center incorporated AI triage into its expanded LDCT screening program in 2023, targeting high-risk individuals (smokers aged 50–74) across multiple major cities.
Cervical Cancer: AI Addressing the Cytologist Shortage
China conducts approximately 70 million cervical cancer screenings per year — the largest national program by volume globally. The bottleneck is trained cytologists to read Pap smear slides, a resource unavailable in many grassroots health centers.
AI cervical cytology tools from companies including Tencent AI and SenseTime have been evaluated in published clinical trials. A study published in The Lancet Digital Health (2021) evaluated an AI-assisted cervical screening approach in a large Chinese cohort and found that AI assistance improved abnormality detection while reducing the proportion of slides requiring human expert review — directly addressing the capacity constraint.
Deployment has extended to grassroots health centers in underserved provinces including Gansu, Guizhou, and Henan, where specialist gynecological expertise has historically been limited.
Colorectal Cancer: Real-Time AI During Colonoscopy
Colorectal cancer is China's second most common cancer by incidence. The adenoma miss rate during colonoscopy — a key quality indicator — averages 20–26% in routine clinical practice and is highly operator-dependent.
AI systems that provide real-time polyp detection during colonoscopy have been evaluated in multiple randomized controlled trials at Chinese hospitals. The EndoAngel system, developed by Wuhan EndoAngel Medical Technology, became one of the first AI-assisted colonoscopy systems to receive NMPA clearance in 2020. A landmark RCT conducted at Renmin Hospital of Wuhan University and published in Gastroenterology (2019) showed statistically significant improvement in adenoma detection rate with AI assistance. The system has since been deployed in over 300 hospitals.
What This Means for International Patients
International patients treated at Class 3A hospitals in China benefit from AI-augmented diagnostics as a routine part of the clinical workflow. AI-assisted CT reading, AI colonoscopy guidance, and AI pathology support are increasingly standard at leading institutions — improving both speed and accuracy of the diagnostic process at costs well below comparable Western centers.
Sources: The Lancet Digital Health, 2021 (AI cervical screening); Gastroenterology, 2019 (EndoAngel colonoscopy RCT, PMID: 30630050); Infervision clinical deployment data; NMPA AI medical device registry 2025; China National Cancer Center screening program 2023.